Navigation Links
Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
Date:6/14/2008

MONTREAL, June 14 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") today presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia ("CIA") at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.

Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data on PBI-1402 in a poster entitled "PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia". Results demonstrated that a once daily oral treatment of PBI-1402 induces a significant increase in hemoglobin ("Hb") level, red blood cell ("RBC") count and hematocrit ("Ht") in CIA patients. Furthermore, results suggest that PBI-1402 can reduce the need for RBC transfusion, since only 6% of patients in the clinical trial required transfusion.

"Subsequent positive data compiled from the 28 patients having completed the PBI-1402 CIA clinical trial include the fact that 26 of these patients did not require RBC transfusions while maintaining their full chemotherapy regimen. This data further supports that PBI-1402's current performance is in line with the Food and Drug Administration's ("FDA") recommendation of reducing patient need for RBC transfusions," states Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "Additionally, PBI-1402 offers the added advantage of oral dosing which allows for a convenient management of anemia without interference with other treatments received by the CIA patients."

In the March 13, 2008 briefing document, the FDA's Oncologic Drugs Advisory Committee emphasized that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusions. Approximately 50% of anemic patients receiving chemotherapy require RBC transfusions, and 20%-25% of patients treated with ESAs still require RBC transfusions.
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. QLT announces positive Health Canada decision on Aczone(R)
3. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
4. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
6. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... , , , ... became the only hospital in the Midwest to acquire a dual console ... States to purchase the new system. , , ... the latest robotic-assisted surgery system that gives surgeons an enhanced three-dimensional view ...
... , , , , ... Inc. (Nasdaq: RGDX ) announced today that it has entered ... Partnership to raise approximately $4 million from the private placement of 3,057,907 ... $1.30 per share. The closing of the sale of the shares occurred ...
... , , , ... (NYSE: ARE ), Landlord of Choice to the Life ... long-term lease with Eli Lilly and Company as the anchor tenant ... Science Park ("the Alexandria Center"). Lilly has leased approximately 91,000 ...
Cached Biology Technology:St. John's Hospital Acquires Latest Technology in Robotic-Assisted Surgery 2Response Genetics Announces $4 Million Private Placement 2Response Genetics Announces $4 Million Private Placement 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 2Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 4
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... pay more for meals prepared with produce and meat ... meals actually increases when the price increases, according to ... of how customers perceive and value local food shows ... when they are priced slightly higher than meals made ...
... a poorly understood class of RNA produced in a mammal,s ... of the infection. Their findings are reported today in ... Microbiology. RNA (ribonucleic acid) contains information transcribed from the ... these RNAs translate sections of DNA code into building blocks ...
... New University of Florida research puts to rest the ... glacial period. It turns out it ended up in the ... findings have implications for modern-day global warming, said Ellen Martin, ... paper, which is published in this week,s journal Nature ...
Cached Biology News:Restaurant customers willing to pay more for local food 2New class of biomolecules triggered in response to respiratory virus infection 2New class of biomolecules triggered in response to respiratory virus infection 3New class of biomolecules triggered in response to respiratory virus infection 4UF research gives clues about carbon dioxide patterns at end of Ice Age 2UF research gives clues about carbon dioxide patterns at end of Ice Age 3
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... PCR Enhancer (with betaine) substantially improves ... and specificity for amplification of many ... in PCR eliminates the base-pair composition ... thermal stability, suppresses pauses of DNA ...
... Systems provide rapid, precise localization of ... frozen or paraffin-embedded tissue, cytospins and ... facilitate double or triple labeleing experiments, ... with primary antibodies of different animal ...
Biology Products: